University of Hyderabad and Krismo Biosciences Partner to Develop Novel Therapies for Inflammatory Diseases and Viral Infections
• The University of Hyderabad (UoH) and Krismo Biosciences have formed a strategic partnership to develop next-generation therapies targeting inflammatory diseases and serious infectious conditions including Dengue, COVID-19, and Influenza.
• The collaboration will leverage academic expertise and industry innovation to design antibody-based therapeutics against viral infections and bacterial toxins, with a comprehensive approach including preclinical toxicology and non-GLP studies.
• Facilitated by UoH's Technology Enabling Centre (UoH-TEC), this public-private partnership exemplifies the growing trend of translational academic research in India aimed at addressing urgent healthcare challenges with practical, affordable solutions.
Nose-to-Brain Drug Delivery Shows Promise for Treating Central Nervous System Tuberculosis
• Indian scientists have developed a novel nose-to-brain drug delivery method for treating Central Nervous System Tuberculosis (CNS-TB), a severe form of the disease.
• The method utilizes chitosan nano-aggregates to transport TB drugs directly to the brain, bypassing the blood-brain barrier and improving drug bioavailability.
• In mice studies, nasal delivery of nano-aggregates significantly reduced bacteria in the brain compared to untreated subjects, demonstrating therapeutic effectiveness.
• This approach could potentially be applied to treat other brain infections, neurodegenerative diseases, brain tumors, and epilepsy by enabling efficient drug delivery.
© Copyright 2025. All Rights Reserved by MedPath